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Background: Nowadays, short dental implants are being increasingly applied in extremely resorbed posterior regions.
The recent studies have indicated that short implants present a similar success rate to conventional implants. It is
assumed that short implants can avoid additional surgical morbidity and are less technically demanding. However,
high-quality evidence (≥Ib: evidence from at least one randomized controlled trial) on comparing the clinical outcome
of short implants and longer implants combined with osteotome sinus floor elevation (OSFE) technique is limited.
Methods/Design: The proposed study is designed as a prospective single-center, three-arm parallel group, randomized
controlled trial. We plan to enroll 150 patients in need of dental implant treatment in the posterior maxilla. The inclusion
criteria include: age ≧18 years, partial edentulism in the posterior maxilla for at least 3 months from tooth loss, residual
bone height ranging from 6 to 8 mm, sufficient bone width (≥6 mm) in the edentulous region. The patients will be
divided into three groups according to a table of random numbers: group 1: short implants (6 mm) alone; group 2: short
implants (8 mm) combined with osteotome sinus floor elevation (OSFE); group 3: standard implants (10 mm) combined
with OSFE. The assignment will be concealed from the clinical operators until the beginning of implant surgery. The
outcome examiners and patients will be kept blinded to the assignment. Implant survival rates, implant success rates,
complications, resonance frequency analysis (RFA) measurements, marginal bone level, treatment time and
patient-reported outcome (visual analogue scale for intraoperative discomfort and postoperative pain) will be
recorded. Clinical re-evaluations will be performed at 12, 24, 36 and 60 months after crown placement.
Discussion: The results of the trial will support better decision-making for dental implant treatment in atrophic
maxillary ridges. If favorable, the use of short implants may avoid adjunct procedures used for implant insertion,
thus reducing operative time, complexity and postoperative discomfort.
Trial registration: Clinicaltrials.gov identifier: NCT02350075 (registered on 17 February 2015).
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Implant treatment in the posterior maxilla is commonly
faced with great challenges due to the limited residual
bone height (RBH) and poor bone quality [1]. A cone-
beam computed tomographic analysis study based on
199 sinuses showed that RBH ≤4 mm was observed in
46.9 % and 48.9 % of edentulous first and second molar
sites [2]. Efforts have been made to allow successful im-
plant treatment in atrophic posterior maxillae. Accord-
ing to current evidence, osteotome sinus floor elevation
(OSFE) has been proven to be a predictable surgical pro-
cedure with a high success rate to vertically increase the
bone volume in atrophic maxilla when the RBH ranges
from 6 to 8 mm [3]. However, the additional surgical
procedure is technically demanding, and may increase
postoperative morbidity and the total cost [4].
As an alternative, short implants are being increasingly
applied in extremely resorbed posterior regions. The defi-
nitions of short implants varied in the literature. Authors
defined implant length less than 11 mm [5], 10 mm [6] or
8 mm [7] as short implants. Telleman argued that because
an implant could be placed at a different horizontal level,
a short implant should be defined as an implant with a de-
signed intrabony length of 8 mm or less [8].
A recent meta-analysis has indicated that short implants
present a similar success rate to conventional implants and
the implant length is no longer considered a crucial factor
in influencing implant success [9]. However, contradictory
results are reported when short implants are inserted in the
posterior maxilla. A retrospective cohort study of 4591
Straumann (Standard, Standard Plus, Tapered Effect and
Bone Level) implants with up to 10-year follow-up showed
that short 6-mm implants in the mandibular posterior sites
had a high survival rate of 100 %, while in maxillary poster-
ior positions a survival rate of only 87 % was achieved [10].
On the other hand, several studies reported an acceptable
clinical outcome (survival rates range from 90.0 % to
98.3 %) using short implants (5 mm, 6 mm and 7 mm) in
the treatment of the posterior maxilla with up to 5–10
years follow-up [11, 12].
To our knowledge, three randomized controlled clin-
ical trials compared short implants versus longer im-
plants in combination with OSFE procedures in the
posterior maxilla [13–15]. Similar survival rates were
reported in short and longer implant groups after a 1-
year follow-up. However, the limited sample size (101
patients in Thoma et al. 2015 [14], 41 patients in Gujie
et al. 2014 [13] and 30 patients in Esposito et al. 2014
[15]) might lead to insufficient statistical power. In
addition, the lateral sinus floor elevation technique was
performed in those patients with RBH from 5 to 8 mm,
while the OSFE technique might be more suitable from
cost-effectiveness considerations. Thus, there is still an
urgent need for randomized controlled clinical trialswith long-term data and a sufficient sample size to
provide more clinical evidence to decide the best treat-
ment options.
Based on these, we are now designing a randomized
controlled trial study with a 5-year follow-up trying to
answer the research question: which is the best treat-
ment option in atrophic maxilla with RBH from 6 to
8 mm: short 6-mm implants alone or short 8-mm im-
plants combined with OSFE or standard 10-mm im-
plants combined with OSFE?
Objective and hypotheses
The aim of the study is to evaluate the clinical success
and the patient-reported outcome of intraoperative and
postoperative pain of short implants (6 mm) alone, short
implants (8 mm) combined with OSFE and standard im-
plants (10 mm) combined with OSFE for treating atro-
phic posterior maxillary ridges of partially edentulous
adults. Considered outcomes include implant survival
rates, complications, resonance frequency analysis (RFA)
measurements, marginal bone level, treatment time and
patient-reported outcome (visual analogue scale for
(VAS) intraoperative discomfort and postoperative pain)
Method/Design
Overview
The proposed study is designed as a prospective single-
center, three-arm parallel group, randomized controlled
trial. We plan to enroll 225 patients in need of dental
implant treatment in the posterior maxilla. The study
(Number [2015]16) has been approved by the Ethics
Committee of Shanghai Ninth People’s Hospital, China.
In addition, the study has been registered in Clinical-
Trials.gov and the identifier number is NCT02350075.
The clinical component of the study will be initiated in
September 2015 at the Department of Oral and Maxillo-
facial Implantology, Shanghai Ninth People’s Hospital,
Shanghai Jiao Tong University, China.
The systematic health condition of all the participants
will be recorded and they should fulfill the following
criteria. Before the implant surgery, all patients will re-
ceive clinical and radiographic assessment. All patients
will be required to receive oral hygiene instructions be-
fore implant surgery. Panoramic and periapical radio-
graphs will be taken to assess the initial bone height
and width. If necessary, cone-beam computed tomog-
raphy will be performed.
Inclusion criteria
a. Aged over 18 years old
b. Partial edentulism (all incisors and canines present)
for at least 3 months from tooth loss
c. Residual bone height ranging from 6 to 8 mm
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(≥6 mm)
Exclusion criteria
a. Medically compromised patients (American Society
of Anesthesiologists (ASA) classification III–IV)
b. Heavy smokers (>10 cigarettes/day)
c. Uncontrolled diabetes mellitus
d. Complete edentulism
Recruitment
Recruitment will be performed in the Department of
Oral and Maxillofacial Implantology, Shanghai Ninth
People’s Hospital. Eligible patients will receive the study
information and consent forms. No patients will be in-
cluded in the study until the consent forms are signed.
Allocation and blinding
The patients will be divided into three groups using
randomization tables allocating the patient a number
within a corresponding envelope: group 1: short im-
plants (6 mm) alone; group 2: short implants (8 mm)
combined with OSFE; group 3: standard implants
(10 mm) combined with OSFE. The assignment will be
concealed from the clinical operators until the beginning
of implant surgery. The outcome examiners and patients
will be kept blinded to the assignment.
Surgical procedures
For all the cases, Straumann (Institute Straumann AG,
Basel, Switzerland) Standard Plus implants will be
placed. Following a mid-crestal incision, a full-thickness
mucoperiosteal flap will be reflected. In group 1, 6-mm
implants will be inserted according to the manufacturer’s
instructions. In group 2, after implant, the site will pre-
pared to a depth of about 1–2 mm away from the sinus
floor, a modification of Summers’ OSFE will be performed
to elevate the sinus membrane to a depth of 8 mm. In
group 3, similar procedures will be performed until the
sinus membrane is elevated to a depth of 10 mm. The
OSFE procedure has been described in detail previously
[16]. After surgery, anti-inflammatory amoxicillin (Xinya
Co., Shanghai, China, 500 mg, three times a day for 7 days)
and metronidazole (Xinyi Wanxiang, Shanghai, China,
400 mg, three times a day for 7 days) will be used. In
addition, chlorhexidine oral rinse (0.12 %) will be pre-
scribed for 60 s two times a day for 14 days. A one-stage
protocol will be performed. After a healing time of 3–4
months, an impression will be taken at the implant level.
Straumann synOcta titanium abutments will be fixed
onto the implants. Porcelain (Ivoclar Vivadent AG,
Schaan, Liechtenstein) fused to noble metal (HeraeusKulzer Corporation, Hanau, Germany) crowns and
bridges will be fabricated.
Outcomes
Baseline assessment
Resonance frequency analysis (RFA) measurements, treat-
ment time and patient-reported outcome will be recorded.
RFA assessment will be performed immediately after
surgery, 2 weeks later and 3 months after surgery. RFA
measurements will be conducted by the Osstell™ mentor
(Integration Diagnostics AB, Göteborg, Sweden). Treat-
ment time will be calculated from incision beginning to
suture finishing. Patients will be asked to give their an-
swers regarding intraoperative discomfort and postopera-
tive pain immediately and two weeks after surgery using a
100-mm visual analogue scale (VAS) with word descrip-
tors "very dissatisfied" to "very satisfied" on the left and
right respectively.Follow-up assessment
All the included patients will be recalled for clinical and
radiographic assessment at 12, 24, 36, and 60 months
after crown placement. Survival rates, complication rates
and marginal bone level will be recorded. Implant sur-
vival rates are defined as the percentage of implants still
retained in the mouth. Implant success is defined ac-
cording to Cochran et al. 2002 [17]. Both biological and
mechanical complications will be recorded. Periapical ra-
diographs will be taken immediately after implant sur-
gery, and at the 1-year, 3-year, and 5-year examination.
For standardization, a paralleling technique with a Rinn
film holder (XCP Instruments; Rinn Corporation, Elgin,
IL, USA) will be conducted. Radiographic analysis will
be conducted by a software program (SIDEXIS 1.12;
Sirona Dental Systems GmbH, Bensheim, Germany).
Biological complications refer to peri-implant mucositis
(bleeding on probing positive, and without surrounding
bone loss) and peri-implantitis (bleeding on probing
positive, probe pocket depth ≥5 mm and with surround-
ing bone loss), and technical complications are veneer
ceramic chipping, framework fracture, loss of retention,
screw loosening, abutment and implant fracture.
Sample size
The primary outcome is the implant survival rate. The
criterion for significance is set at α = 0.05 (type I error)
and at β = 0.10 (type II error). The analysis is two-tailed.
The survival rate reported by Esposito et al. 2014 (92 %
in the longer group and 85.7 % in the short group) is
used to estimate the sample size [15]. Forty-two cases
per group can result in a power of 80 %. Assuming the
dropout rate at 20 %, 50 cases per group and 150 cases
in total are finally determined.
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Generalized estimating equations will be used to manage
the correlated relationships between multiple implants
in the same patient. The data of different patients are as-
sumed to be independent. Each patient will be assigned
a number, which will be an indicator (X) for primary
and secondary outcome (Y). For the patient (i) and im-
plants (j), mean model is logit(E(Yij|Xij)) = beta0 +
beta1*I(Xij = 2) + beta2*I(Xij = 3), and variance model is
Var(Yij|Xij) = E(Yij|Xij)*(1-E(Yij|Xij)). For patient-reported
outcome (VAS), ANOVA will be used to assess the differ-
ence among the three groups. The level of significance is
set at 0.05.
Missing data
Sample size calculation was performed accounting for
possible loss to follow-up. Moreover, we will account for
the data not missing at random due to unbalanced loss
to follow-up by handling drop-outs as nonsuccess or
nonsurvival using the intention-to-treat principle.
Ethical considerations
Ethical approval
The study has been approved by the Ethics Committee
of Shanghai Ninth People’s Hospital, China (Number
[2015]16). Eligible patients will receive the study infor-
mation and consent forms. No patients will be included
in the study until the consent forms are signed.
Withdrawal
Patients will be informed that they have the right to
withdraw from the study at any time without giving rea-
sons. Regardless of withdrawal, patients will be provided
with any treatment requested by them.
Dissemination of results
The results of the study will be published in inter-
national peer-reviewed journals. A summary of the study
results will also be saved at Clinicaltrials.gov to allow
general access to obtain findings.
Discussion
Implant treatment in the posterior maxilla is commonly
faced with great challenges due to the limited residual
bone height and poor bone quality. In 2013, our study
demonstrated that high survival rates can be achieved
after 5–10years for Straumann SLA Standard Plus short
implants (6 or 8 mm) in the posterior region, without
severe marginal bone loss and complications [18]. This
result shows that Straumann short 6-mm implants are
predictable and reliable in the posterior maxilla. In
addition, our previous studies have also indicated that
the OSFE technique is also predictable and reliable in
the posterior maxilla [16, 19]. Therefore, our researchgroup is very interested in the long-term treatment out-
come of short implants alone and longer implants com-
bined with OSFE.
The results of the trial will support better decision-
making for dental implant treatment in atrophic maxil-
lary ridges. If favorable, the use of the short implant may
avoid adjunct procedures used for implant insertion,
thus reducing operative time, complexity and postopera-
tive discomfort.
Trial status
The trial was registered at Clinicaltrials.org and the
study is open for recruitment.
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